MAPT and Huntington disease: In 2015, tau was quantified by enzyme-linked immunosorbent assay (ELISA) for the first time in the CSF of patients with HD: the CSF tau level distinguished between the healthy controls and the carriers of HD gene expansion (premanifest and manifest evaluated together).